Skip to playerSkip to main content
  • 1 week ago
Weight-loss drugs are becoming a popular employee perk, with almost a third of workers saying they’d switch jobs to get GLP-1 coverage.

Now, Bank of America is spending $250 million or more yearly on the drugs for its staffers—and CEO Brian Moynihan says the upsides are well-worth the eye-watering cost.

Category

🤖
Tech
Transcript
00:00Bank of America is spending more than $250 million annually on covering weight loss drugs for its
00:05employees. Some companies like PwC, HCA Healthcare, and Cigna all once offered GLP-1 treatment for
00:13employees, whether it be weight loss reasons or whether it be type 2 diabetes. But now these
00:19companies have since rescinded back on the qualifications that it needs to cover GLP-1s.
00:24Currently about 10% of Americans are on GLP-1s for weight loss purposes. Even though production's
00:30ramping up, supply is ramping up, a lot of companies are now having to grapple with the
00:35constant costs of covering these drugs for their employees. About 60% of employers offer it for
00:41just type 2 diabetes, but other companies, around 36%, offer it for weight loss purposes and for type 2.
00:48There's a lot of benefits to offering GLP-1 coverage to employees. 30% of workers say that
00:55they would even switch jobs if they had the opportunity to actually get this coverage in
01:00another path. I think in terms of talent, we're seeing a lot of interest from professionals wanting
01:05to work in environments that offer these kinds of treatments.
Comments

Recommended